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ABSTRACT We employ ab initio electronic structure calculations to obtain two structural models for copper bound in the
strongest binding site of the noninfectious form of the prion protein. The models are compatible with available experimental
constraints from electron spin resonance data. The bending of the peptide backbone attendant with the copper binding is not
compatible with the requisite straight b-strand backbone structure for the same sequence contained in two recently proposed
models of the prion protein structure in its infectious form. We hypothesize that copper binding at this site is protective against
conversion to the infectious form, discuss experimental data that appear to support and conﬂict with our hypothesis, and
propose tests using recombinant prion protein, genetically modiﬁed cultured neurons, and transgenic mice.
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The functional role of the normal cellular prion protein
(PrPC) may well be related to copper binding, potentially
protecting against oxidative damage in the synaptic region
by sequestering divalent copper (1). This suggestion is sup-
ported by data for transgenic knockout mice devoid of the
gene for expressing PrPC; these mice appear to suffer late
stage oxidative degradation in the neuronal synaptic regions
where surface bound prion protein is preferentially concen-
trated in wild-type mice (2,3). The strongest copper binding
site is in the protein region that converts to b-sheet structure
in the infectious (PrPSc) form (1). We use electronic structure
calculations to study two possible geometries for the bound
copper-PrPC complex; we ﬁnd that these geometries are in-
compatible with recently proposed models (4,5) for PrPSc
oligomers, and we thus hypothesize a mechanism for inhi-
bition of PrPC-to-PrPSc conversion via copper binding.
Copper binds principally to mammalian PrPC at octarepeat
sites of highly conserved form (though not number) in a now
well-understood pyramidal geometry with binding to the
peptide backbone, histidine side chains, and axial waters (6).
These octarepeats (residues 60–91 in humans) are not es-
sential to PrPSc, which remains infectious even after protein-
ase exposure that leaves residues 92–230 intact. One strong
copper binding site is present in the PrPSc core region, con-
taining the sequence 92–96 GGGTH for humans. Electron
spin resonance data suggest there is binding to the H96 (H95
in mice) side chain and the G94 amide group (1). It is not
known whether the primary peptide coordination is to four
nitrogens (NNNN) or to three nitrogens and an oxygen
(NNON), although the former structure has been conjectured
to be more likely (1).
We have studied this problem computationally with the
SIESTA local orbital-based density functional theory code
using conjugate gradient-based energy minimization to ex-
amine possible GGGTH-Cu(II) geometries (7,8). We have
considered the NNNN structure and an NNON structure
compatible with the ESR data (1) and our results are shown
in the upper two panels of Fig. 1 for the mouse prion. We
built initial candidate structures of the form Ac-Cu(H2O)6
(GGGTH)-NH2 using ChemSite Pro (ChemSW, Fairﬁeld,
CA) and VMD (9). For each geometry, the lowest energy
sampled provides our model bound copper-prion complex.
We used double-zeta (DZ) basis sets for light atoms (H, C, N,
O) and double-zeta polarized orbitals for copper. We used
the Troullier-Martins norm-conserving pseudopotential. We
employed the Perdew-Becke-Ernzerhof-based generalized
gradient approximation exchange correlation energy func-
tional. Our energy cutoff for matrix element integration was
120 Rydberg. All calculations were carried out in a periodic
unit cell size: 30.73 30.73 30.7 A˚. Geometry minimization
was carried out to a force tolerance of 32 pN.
Our main result is inferred from comparing the two pos-
sible GGGTH-Cu(II) geometries to recently proposed
b-helical PrPSc trimer models (4,5). We see that the backbone
bending induced by copper binding is not compatible with
formation of b-strands in the left-handed helices. (It is un-
clear if another recently proposed model has the same char-
acteristics (10).) Hence, copper in the nonoctarepeat sequence
GGGTH can protect against PrPC-to-PrPSc conversion; re-
moval of this copper by pH reduction associated with synaptic
ﬂuctuations or endocytosis may be a key step in the conversion
pathway. This picture is supported by the observation that only
the GGTH sequence is required for binding, and eutherian
prion sequences reveal high conservation of either GGTH or
the very similar GGSH sequence in the converting region (11).
Removal of this copper by pH reduction may be a key step
in the PrPC-to-PrPSc conversion pathway because it is known
that acidic conditions favor detachment of the copper (12).
We note two routes for such a pH reduction with accom-
panying conversion of PrPC. First, upon endocytosis into the
cell, the pH is reduced. Assuming that some PrPSc is endo-
 2006 by the Biophysical Society
doi: 10.1529/biophysj.106.083642
Biophysical Journal: Biophysical Letters
Biophysical Journal: Biophysical Letters L11
cytosed as well as PrPC, then conversion can take place within
the endocytosed compartments after the copper is expelled.
Second, given that PrPC is preferentially concentrated near
the synapse, then from signal bearing vesicles released near
or at the synapse (13) can reduce the pH locally and facilitate
copper expulsion.
Three experimental results support our proposed mecha-
nism indirectly: 1), Postmortem studies show copper deple-
tion in regions of infection, with 80–90% reduction of copper
content in the corresponding prion proteins (14). This result
is consistent with our mechanism, since this GGGTH binds
Cu(II) ﬁrst with potential cooperative enhancement of sub-
sequent binding to other sites. If infection promotes removal
of copper from this site, then it is more likely that copper will
not be retained at the other sites assuming near-equilibrium
conditions. 2), Copper uptake in infected cultured neurons is
suppressed ;10-fold compared to control cells (15). Again,
this is consistent with the hypothesis, although this requires
an understanding of how the prion, which is easily shown
to contain ,1% of cellular copper, can shut down copper
transport. 3), Copper in solution inhibits in vitro growth of
amyloid ﬁbrils (16,17). This is a more direct corollary to our
hypothesized protective role of copper.
Other experiments provide mixed support for our mech-
anism. The copper chelator D-penicillamine inoculated in
vivo delays disease onset, which is at apparent odds with our
hypothesis (18). The chelator cuprizone, however, is known
to induce a spongiosis (vacuolation of brain tissue) very
similar to that of prion disease although it also induces
demyelination of neurons and no transmissibility (19,20).
Moreover, it is also known that copper confers proteinase
resistance to the cellular prion protein in the weaker binding
octarepeat regions (21). This is signiﬁcant for two reasons.
First, proteinase resistance is one of the generic hallmarks of
the infectious form of the disease (although not all infectious
prion protein is in fact proteinase resistant). Second, the
octarepeat deletion does not remove infectivity from PrPSc.
However, in transgenic mice without octarepeats, disease
incubation upon direct intercerebral inoculation is slowed
(22). Hence, these octarepeats are not necessary for disease,
but i), they can impart structure in the presence of copper that
confers proteinase resistance to the prion protein, and ii),
their presence enhances disease incubation. Indeed, it is
known that the octarepeat region adopts a unique structural
motif when copper is bound (23). We can rationalize these
data by assuming the following afﬁnity ranking: cuprizone.
nonoctarepeat site . D-PEN . octarepeat site. This ranking
is plausible given the hexadentate chelation of cuprizone
versus at most tetradentate coordination of D-PEN. With this
assumption, D-PEN lifts the proteinase resistant structure
associated with copper binding to octarepeats, and this slows
conversion to the infectious form. These assumptions may be
tested by performing competitive binding experiments in
vitro with D-PEN (18), cuprizone (19), and the relevant
copper binding segments of the prion protein. We note that
the high afﬁnity of cuprizone for divalent copper apparently
leads to stripping of copper from other proteins so that the
in vivo phenomena need not be limited to prions; if our as-
sumptions are correct, these nonprion related effects must
lead to more rapid degeneration of neurons than conversion
to PrPSc.
To further test the mechanism, it is desirable to perform
mutation studies on the stretch GGSH or GGTH. The key
idea is to mutate out the H for, e.g., A,Y,G or other amino
acids which should severely mitigate copper binding. We
propose ﬁrst that recombinant mutant PrPC from residues
90–230 (with, e.g., H96A in the human form) be allowed
to aggregate in copper-full and copper-free environments.
Using the reduced length prion will avoid the confounding
effects from the octarepeat regions discussed above. If the
mechanism is correct, the ﬁbril formation rate should be
approximately the same as wild-type ﬁbrils grown in copper-
free solutions. Second, one can transfect cultured neurons
with the mutated DNA construct and look for increased
susceptibility to infection. Third, assuming positive results
from the ﬁbril growth and cultured neuron experiments,
transgenic mice with the H95 mutated away; these mice
should prove to have shorter incubation times for a given
dose than wild-type mice. Finally, ﬁbrillization experiments
on recombinant marsupial PrPC with and without copper
should be informative since the H is replaced with Y24; our
prediction based upon the present hypothesis would be that
FIGURE 1 Potential copper binding motifs in the converting
region of the normal (PrPC) mouse prion protein, which are
consistent with ESR data (1) are shown in panels a and b. The
corresponding copper-free stretch of the left-handed b-helix
model of the infectious (PrPSc) protein from Govaerts et al. (4)
is shown in panel c.
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the copper should have reduced inhibition of ﬁbril formation
relative to growth of recombinant human prion protein.
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